ENTITY

AgomAb Therapeutics (AGMB US)

9
Analysis
Health Care • Belgium
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications. The company's pipeline includes small molecule and antibody product candidates, such as Ontunisertib (AGMB-129) for Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis. AgomAb Therapeutics was founded in 2017 and is headquartered in Antwerp, Belgium.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x